- Home
- HALO
as 07-26-2024 4:00pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 6.5B | IPO Year: | N/A |
| Target Price: | $58.38 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.42 | EPS Growth: | 84.73 |
| 52 Week Low/High: | $32.83 - $57.05 | Next Earning Date: | 08-06-2024 |
| Revenue: | $862,989,000 | Revenue Growth: | 22.41% |
| Revenue Growth (this year): | 21.43% | Revenue Growth (next year): | 16.29% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Jul 22 '24 | Sell | $54.25 | 992 | $53,818.98 | 15,480 | SEC Form 4 |
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Jul 22 '24 | Sell | $53.85 | 4,008 | $215,842.82 | 15,480 | SEC Form 4 |
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Jun 26 '24 | Sell | $51.82 | 10,000 | $518,200.00 | 15,480 | SEC Form 4 |
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Jun 26 '24 | Sell | $51.93 | 10,000 | $519,340.00 | 15,480 | SEC Form 4 |
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Jun 26 '24 | Sell | $52.04 | 10,000 | $520,400.00 | 15,480 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Jun 18 '24 | Sell | $49.43 | 10,000 | $494,260.00 | 168,176 | SEC Form 4 |
| Posard Matthew L. | HALO | Director | Jun 11 '24 | Sell | $50.01 | 10,000 | $500,110.00 | 109,755 | SEC Form 4 |
| Posard Matthew L. | HALO | Director | Jun 11 '24 | Sell | $50.62 | 10,000 | $506,190.00 | 99,755 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | May 21 '24 | Sell | $45.16 | 10,000 | $451,640.00 | 168,176 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | May 21 '24 | Sell | $45.38 | 10,000 | $453,840.00 | 168,176 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Apr 16 '24 | Sell | $38.35 | 10,000 | $383,500.00 | 168,176 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Apr 16 '24 | Sell | $38.49 | 10,000 | $384,890.00 | 168,176 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Mar 12 '24 | Sell | $41.64 | 10,000 | $416,370.00 | 156,558 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Mar 12 '24 | Sell | $42.27 | 10,000 | $422,730.00 | 156,558 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Feb 27 '24 | Sell | $39.95 | 10,000 | $399,460.00 | 159,087 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Feb 27 '24 | Sell | $39.56 | 2,529 | $100,044.71 | 156,558 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Feb 27 '24 | Sell | $39.54 | 7,471 | $295,418.28 | 156,558 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Jan 16 '24 | Sell | $36.00 | 10,000 | $360,000.00 | 151,911 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Jan 16 '24 | Sell | $36.00 | 10,000 | $360,000.00 | 151,911 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Dec 12 '23 | Sell | $39.58 | 9,357 | $370,303.28 | 152,554 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Dec 12 '23 | Sell | $40.47 | 643 | $26,019.00 | 151,911 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Dec 12 '23 | Sell | $40.39 | 10,000 | $403,940.00 | 151,911 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Nov 14 '23 | Sell | $39.08 | 8,292 | $324,043.07 | 151,911 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Nov 14 '23 | Sell | $39.08 | 1,708 | $66,746.93 | 151,911 | SEC Form 4 |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Nov 14 '23 | Sell | $39.79 | 10,000 | $397,880.00 | 151,911 | SEC Form 4 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Zacks
10 hours ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
Zacks
10 hours ago
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
MT Newswires
2 days ago
Halozyme Therapeutics Insider Sold Shares Worth $1,100,023, According to a Recent SEC Filing
Argus Research
3 days ago
HALO: What does Argus have to say about HALO?
MT Newswires
3 days ago
Halozyme Therapeutics Insider Sold Shares Worth $269,662, According to a Recent SEC Filing
Zacks
3 days ago
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Zacks
3 days ago
Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy
PR Newswire
3 days ago
Halozyme to Report Second Quarter 2024 Financial and Operating Results
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.